|
Apr 8
|
Novo Nordisk parent refiles US application on Catalent deal
|
|
Apr 8
|
UPDATE 1-Novo Nordisk parent refiles US application on Catalent deal
|
|
Apr 8
|
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
|
|
Apr 7
|
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
|
|
Apr 7
|
10 Best Weight Loss Drug Stocks to Buy Now
|
|
Apr 6
|
Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
|
|
Apr 6
|
Is it Too Late to Buy Viking Therapeutics Stock?
|
|
Apr 5
|
IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin
|
|
Apr 4
|
After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves
|
|
Apr 4
|
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
|
|
Apr 3
|
Hedge Fund Favorites: 3 European Stocks Attracting Significant U.S. Investment
|
|
Apr 3
|
UPDATE 1-Novo says Ozempic starter kits still not available in Germany in Q2
|
|
Apr 1
|
Meet The "Magnificent Seven" of Healthcare Stocks
|
|
Apr 1
|
20 Most Obese Countries in Asia
|
|
Mar 31
|
Is Novo Nordisk the Best Healthcare Stock for You?
|
|
Mar 31
|
Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why.
|
|
Mar 31
|
Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock
|
|
Mar 30
|
20 Countries with the Highest Age Dependency Ratio in the World
|
|
Mar 29
|
Ozempic Could Sell at a Profit for $57 a Year, Report Says. It’s Priced at $11,600.
|
|
Mar 29
|
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
|